Katherine Dawn Wysham is a Seattle, Washington based female rheumatologist who is specialized in Rheumatology. Active license number of Katherine Dawn Wysham for Rheumatology is MD61008475 in Washington. Katherine Dawn Wysham treat joint disease similar to orthopedists but do not perform surgeries. She diagnose and treat diseases of joints, muscle, bones and tendons which includes arthritis, back pain, muscle strains, common athletic injuries and 'collagen' diseases.
Complete Profile:
Katherine Dawn Wysham speciality, credentials, practice address, contact phone number and fax are as below.
Patients can directly walk in or can call on the below given phone number for appointment.
Specialization:
Rheumatology
Gender:
Female
Practice Address:
1660 S Columbian Way # 151-a, Seattle, Washington, 98108-1532
Phone:
206-277-3293
Fax:
206-764-2903
Professional Identification Codes:
NPI number stands for National Provider Identifier which is a unique 10-digit identification number issued to health care providers in the United States by the Centers for Medicare and Medicaid Services (CMS).
NPI details are as mentioned below.
NPI Number:
1558637561
NPI Enumeration Date:
24 Mar, 2012
NPI Last Update On:
03 Dec, 2020
Medical Licenses:
Doctors can have one or more medical licenses for different specialities in the same state or different states. Related medical licenses for Katherine Dawn Wysham are as mentioned below.
License Number
Specialization
State
Status
MD61008475
Rheumatologist
Washington
Primary
Business Mailing Address:
Business mailing address can be used for mailing purpose only, for visiting purpose patients need to refer above mentioned address.
Address:
1660 S Columbian Way # 151-a, Seattle, Washington
Zip:
98108-1532
Phone Number:
206-277-3293
Fax Number:
206-764-2903
Patients can reach Katherine Dawn Wysham at 1660 S Columbian Way # 151-a, Seattle, Washington or can call to book an appointment on 206-277-3293. Data of this site is collected from Medicare & Medicaid Services (CMS) and NPPES. Last updated on 11 March, 2024.